Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients
This study has been completed.
Study NCT00653406 Information provided by Janssen Pharmaceutical K.K.
First Received on April 1, 2008. Last Updated on May 16, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
More general conditions related to this trial
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
Risperidone long acting injectable
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Central Nervous System Agents
Central Nervous System Depressants
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sponsors listed in this trial
Janssen Pharmaceutical K.K.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers